×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AQST – aquestive therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AQST
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/5
07:14 pm
aqst
Investor Notice: Robbins LLP Informs Investors of the Aquestive Therapeutics, Inc. Class Action Lawsuit
Low
Report
Investor Notice: Robbins LLP Informs Investors of the Aquestive Therapeutics, Inc. Class Action Lawsuit
3/5
07:11 pm
aqst
Aquestive Therapeutics Inc (AQST) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Legal ... [Yahoo! Finance]
Neutral
Report
Aquestive Therapeutics Inc (AQST) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Legal ... [Yahoo! Finance]
3/5
06:02 pm
aqst
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Aquestive Therapeutics, Inc. Securities and Sets a Lead Plaintiff Deadline of May 4, 2026
Low
Report
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Aquestive Therapeutics, Inc. Securities and Sets a Lead Plaintiff Deadline of May 4, 2026
3/5
09:35 am
aqst
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Medium
Report
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
3/4
04:31 pm
aqst
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
3/4
04:01 pm
aqst
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Low
Report
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
3/3
09:13 am
aqst
AQST SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Low
Report
AQST SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
2/28
08:13 am
aqst
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Medium
Report
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Date
Time
Symbol
Company Name
Action
%Chg
3/4/2026
04:01 pm
AQST
aquestive therapeutics, inc.
MISS
Report
-2.1%
aquestive therapeutics, inc.
11/5/2025
04:01 pm
AQST
aquestive therapeutics, inc.
MISS
Report
2.2%
aquestive therapeutics, inc.
8/11/2025
04:01 pm
AQST
aquestive therapeutics, inc.
BEAT
Report
2.8%
aquestive therapeutics, inc.
5/12/2025
04:01 pm
AQST
aquestive therapeutics, inc.
MISS
Report
-19.6%
aquestive therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/4
05:20 pm
aqst
Form S-8 Aquestive Therapeutics,
Low
Report
Form S-8 Aquestive Therapeutics,
3/4
04:21 pm
aqst
Form 10-K Aquestive Therapeutics, For: Dec 31
Low
Report
Form 10-K Aquestive Therapeutics, For: Dec 31
3/4
04:11 pm
aqst
Form 8-K Aquestive Therapeutics, For: Mar 03
Low
Report
Form 8-K Aquestive Therapeutics, For: Mar 03
2/26
08:07 am
aqst
Form 8-K Aquestive Therapeutics, For: Feb 26
Low
Report
Form 8-K Aquestive Therapeutics, For: Feb 26
2/2
07:04 am
aqst
Form 8-K Aquestive Therapeutics, For: Jan 30
High
Report
Form 8-K Aquestive Therapeutics, For: Jan 30
1/21
04:46 pm
aqst
Form S-8 Aquestive Therapeutics,
Low
Report
Form S-8 Aquestive Therapeutics,
1/9
07:19 am
aqst
Form 8-K Aquestive Therapeutics, For: Jan 09
High
Report
Form 8-K Aquestive Therapeutics, For: Jan 09
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/5
Form 8-K Aquestive Therapeutics, For: Nov 05
23.6%
4/24 Form 8-K Aquestive Therapeutics, For: Apr 23 17.2%
2/10 Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film 17.0%
12/10 Form 424B5 Aquestive Therapeutics, 16.5%
4/5 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. 14.7%
8/6 Aquestive Therapeutics Announces Positive Topline Results from Libervant™ (Diazepam) Buccal Film Single Dose Crossover Study 11.7%
11/9 Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.8%
3/3 Form 4 Aquestive Therapeutics, For: Feb 29 Filed by: Kendall Keith J 10.7%
3/18 Form 4 Aquestive Therapeutics, For: Mar 16 Filed by: Boyd Peter E. 10.7%
7/2 Form 4 Aquestive Therapeutics, For: Jun 30 Filed by: Schobel Alexander Mark 8.3%
4/24 Form 8-K Aquestive Therapeutics, For: Apr 23 17.2%
2/10 Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film 17.0%
12/10 Form 424B5 Aquestive Therapeutics, 16.5%
4/5 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. 14.7%
8/6 Aquestive Therapeutics Announces Positive Topline Results from Libervant™ (Diazepam) Buccal Film Single Dose Crossover Study 11.7%
11/9 Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.8%
3/3 Form 4 Aquestive Therapeutics, For: Feb 29 Filed by: Kendall Keith J 10.7%
3/18 Form 4 Aquestive Therapeutics, For: Mar 16 Filed by: Boyd Peter E. 10.7%
7/2 Form 4 Aquestive Therapeutics, For: Jun 30 Filed by: Schobel Alexander Mark 8.3%
TOP News Decliners
3/11
Q4/2019 12/31/2019 EPS -0.480 ZacksConsensus -0.450 ActVsEst (0.030) - Miss
-40.0%
1/12 Aquestive Therapeutics Receives FDA Response to Citizen’s Petition -33.9%
12/12 Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock -19.7%
5/8 Q1/2019 3/31/2019 EPS -0.590 ZacksConsensus -0.490 ActVsEst (0.100) - Miss -17.1%
3/12 Aquestive Therapeutics, Inc. (AQST) Q4 2019 Earnings Call Transcript [The Motley Fool] -13.8%
3/15 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. -13.0%
2/26 Form 4/A Aquestive Therapeutics, For: Nov 30 Filed by: Kendall Keith J -10.6%
12/27 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Lake Street Capital. They now have a $10.00 price target on the stock, down previously from $11.00. -9.9%
8/13 Form 4 Aquestive Therapeutics, For: Aug 09 Filed by: Wood Theresa -9.7%
5/20 Aquestive Therapeutics Inc (NASDAQ: AQST) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "sell" rating. -9.3%
1/12 Aquestive Therapeutics Receives FDA Response to Citizen’s Petition -33.9%
12/12 Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock -19.7%
5/8 Q1/2019 3/31/2019 EPS -0.590 ZacksConsensus -0.490 ActVsEst (0.100) - Miss -17.1%
3/12 Aquestive Therapeutics, Inc. (AQST) Q4 2019 Earnings Call Transcript [The Motley Fool] -13.8%
3/15 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. -13.0%
2/26 Form 4/A Aquestive Therapeutics, For: Nov 30 Filed by: Kendall Keith J -10.6%
12/27 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Lake Street Capital. They now have a $10.00 price target on the stock, down previously from $11.00. -9.9%
8/13 Form 4 Aquestive Therapeutics, For: Aug 09 Filed by: Wood Theresa -9.7%
5/20 Aquestive Therapeutics Inc (NASDAQ: AQST) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "sell" rating. -9.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: